ETFChannel.com
AKRO Description — Akero Therapeutics Inc

Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Company Name: 
Akero Therapeutics Inc
Website: 
www.akerotx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding AKRO: 
24
Total Market Value Held by ETFs: 
$131,821,514.78
Total Market Capitalization: 
$2,174,000,000
% of Market Cap. Held by ETFs: 
6.06%
 ETF   AKRO Weight   AKRO Amount 
 VTI   0.00%   $51,627,086         
 IWM   0.05%   $28,841,376         
 VXF   0.02%   $18,195,841         
 IWN   0.10%   $12,121,350         
 PTH   2.88%   $6,743,678         
 DWAS   0.81%   $3,414,231         
 VTWO   0.05%   $3,112,166         
 IWC   0.28%   $2,657,430         
 ITOT   0.00%   $1,374,633         
 VTWV   0.10%   $997,626         
List of all 24 ETFs holding AKRO »
Quotes delayed 20 minutes

Email EnvelopeFree AKRO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.60 out of 4)
60th percentile
(ranked higher than approx. 60% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding AKRO | Akero Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.